These findings collectively indicate that targeting HSP47—either directly or via its upstream regulatory pathways—may effectively disrupt pathological collagen metabolism, offering novel therapeutic opportunities for IPF management. This evidence concerns the gene SERPINH1 and idiopathic pulmonary fibrosis.